Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients

Yiğenoğlu T. N., Başcı S., Şahin D., Ulaş T., Dal M. S., Korkmaz S., ...Daha Fazla

Transfusion and Apheresis Science, cilt.60, sa.6, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 60 Sayı: 6
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.transci.2021.103237
  • Dergi Adı: Transfusion and Apheresis Science
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Anahtar Kelimeler: COVID-19, Mesenchymal stem cell, SARS-CoV-2, Transfusion, Transplantation
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARS-CoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.